Current scientific efforts concentrate on the identification of molecular targets, and numerous algorithms have been proposed for the recognition of the BCR::ABL1-like ALL subtype, including targeted fusion testing, tiered algorithms and broad-based testing [16–19]. The gene discussed is ABL1; the disease is acute lymphoblastic leukemia.